tapebrief
NOC · Q3 2025

NOC · Q4 2025 Earnings

Cautious

Northrop Grumman

Reported January 27, 2026

30-second summary

Northrop closed FY25 with Q4 revenue of $11.71B (+10% YoY), beating the implied Q4 floor of $10.85B and lifting full-year sales to $41.95B — $54M above the high end of October's reset guide. Non-GAAP EPS of $26.34 beat the FY range by $0.29 on Q4 segment OM of 11.2%, and all four segments returned to growth led by Aeronautics +18% driven by F-35 materials timing, TACAMO ramp, and higher B-21/E-2 volume. The cautious read is forward: 2026 revenue guidance of $43.5–44.0B implies only +3.7% to +4.9% growth despite a $95.7B backlog and 1.10x book-to-bill, B-21 production rate acceleration is still excluded from the guide for a third consecutive quarter, and segment OM guidance of $4.85–5.0B implies a margin rate that holds rather than expands off the FY25 11.2% Q4 exit.

Headline numbers

EPS

Q4 FY2025

$7.23

Revenue

Q4 FY2025

$11.71B

+10.0% YoY

Free cash flow

Q4 FY2025

$3.23B

Operating margin

Q4 FY2025

10.9%

Key financials

Q4 FY2025
MetricQ4 FY2025YoYQ3 FY2025QoQ
Revenue$11.71B+10.0%$10.42B+12.4%
EPS$7.23—$7.67-5.7%
Operating margin10.9%—11.9%-100bps
Free cash flow$3.23B—$1.26B+157.6%

Guidance

FY2025 beat across revenue, EPS, and FCF; FY2026 guidance raised with mid-single-digit revenue growth and accelerating segment operating income, while free cash flow reaffirmed.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueFY2025$41.7B - $41.9B$41.954B+$0.054B above guideBeat
EPS (non-GAAP)FY2025$25.65 - $26.05$26.34+$0.29 above guideBeat
Free Cash FlowFY2025$3,050M - $3,350M$3,307MIn-line (near midpoint)Beat
Segment Operating IncomeFY2025$4,275M - $4,375MNot disclosed—Beat

New guidance

MetricPeriodGuideYoY
RevenueFY2026$43.5B - $44.0B+3.6% to +5.1% YoY
EPS (non-GAAP)FY2026$27.40 - $27.90+3.9% to +5.9% YoY
Segment Operating IncomeFY2026$4,850M - $5,000M+11.5% to +17.0% YoY
Sales Growth RateQ1 FY2026Low single digits—

Segment KPIs

Q4 FY2025
SegmentQ4 FY2025YoY
Aeronautics Systems$3.922B+18.0%
Defense Systems$2.147B+7.0%
Mission Systems$3.449B+10.0%
Space Systems$2.859B+5.0%

Other KPIs

Q4 FY2025
SegmentQ4 FY2025
Total Backlog$95.7 billion
Book-to-Bill Ratio (Full Year 2025)1.10x
Segment Operating Margin Rate11.2%
Operating Cash Flow$3.9 billion
Capital Expenditures as % of Sales5.7%
Funded Backlog$43.5 billion
Unfunded Backlog$52.2 billion
Q4 Net Awards$15.9 billion

Management tone

Narrative arc: Sentinel back on track → Generational tailwinds, broad raise → Margin discipline despite revenue retreat → Urgent capacity, but guide still excludes the upside.

The "broad raise" of Q2 and the "selective conviction" of Q3 have converged into an operating-tempo transformation story that the headline guide does not capture. Three quarters ago the framing was generational defense spending; two quarters ago it was margin discipline despite delays; this quarter management explicitly describes a corporate transformation: "we are moving with urgency and proactively bringing innovative solutions to our customers...we are transforming Northrop Grumman." The shift signals that the bull case has moved from "win the cycle" to "rewire the company to win it faster" — yet the FY26 guide of mid-single-digit growth and a roughly flat segment OM rate looks like it was set before that rewiring is reflected in financials.

Capacity language hardened from "expanding" to "tripling." In Q2 management telegraphed doubling tactical SRM capacity to 25,000 units by 2029. Q3 added that capacity exceeded orders and additional CapEx was coming. This quarter the framing escalated again: "effectively tripling our tactical SRM production capabilities at that facility by early 2027...we are making similar investments to expand capacity at our Elkton, Maryland site to triple capacity there by 2030." Pre-committal CapEx ahead of contract awards is a stronger signal than orders themselves on management's read of the sustained demand cycle.

B-21 acceleration moved from "coming months" to "this quarter" — for the third time. Q2 said clarity coming. Q3 said clarity coming. Q4: "Funding for this acceleration has been approved as part of the reconciliation bill, and I am optimistic that we will come to an agreement with the Air Force this quarter." What's new is that funding is confirmed and the deal is named as Q1-deadline. What's unchanged is that the guide "does not yet include an accelerated B-21 production rate" — and Scott Ducharme's Q&A drew out that the $2–3B incremental investment will mean "minimal 2026 EBIT impact; greater impact in 2027, 2028, and into 2029." The upside is real and pushed out.

International went from "generational" to "20+ countries with formal requests." Q2 framed European NATO commitments as the structural tailwind. This quarter the tally is specific: "we've now received formal requests to acquire IDCS from over 20 countries" with 2–3 expected to announce awards in 2026. The shift from architecture-level optimism to formal-request quantification is the cleanest evidence that international is converting, but the conversion-to-revenue lag means 2027 is when it shows up at scale.

Capital allocation pivoted from balanced returns to reinvestment. Q2 returned $700M to shareholders via buybacks and dividends. This quarter Robert Stallard pressed and management confirmed no additional buybacks beyond January 2026 and dividend increase decision deferred to May. Combined with the CapEx step-up and the $2–3B B-21 investment commitment, this is a structural shift toward funding the capacity expansion ahead of the demand it's built for.

Recurring themes management leaned on this quarter:

Speed of delivery and acquisition transformation as competitive moatCapacity expansion across munitions, SRM, and production facilities to meet surging demandUncrewed systems and collaborative combat aircraft as emerging growth vectorsInternational demand surge with 20+ countries formally requesting capabilitiesB-21 production rate acceleration negotiations with funding already approvedSpace domain as emerging warfighting priority with high-margin growth opportunity

Risks management surfaced:

Execution risks on B-21 production rate acceleration agreement with Air ForceSentinel program restructuring complexity and timeline risksDependency on FY26 defense appropriations completion and reconciliation investments moving forwardInternational export approval and foreign policy uncertaintiesSupply chain and labor availability constraints as capacity is tripled

Q&A highlights

Christine Leewag · Morgan Stanley

Asked about the significant conservatism in 2026 revenue outlook given record $96B backlog and 4% growth guidance. Requested sizing of B-21 and FAXX programs not included in guidance and potential upside if they firm up.

Management characterized approach as 'balanced' rather than conservative, citing dynamic environment. Noted B-21, APEX/SAXX, munitions, and Golden Dome are progressing toward contracts but timing uncertain for 2026. Expects these opportunities to materially impact 2027 sales. Declined to size B-21 and FAXX impact on 2026 outlook.

$96 billion record backlog4% year-over-year 2026 growth guidance midpointB-21 and FAXX/SAXX not yet incorporated into 2026 guidanceExpects material sales impact from these programs in 2027

Scott Ducharme · Deutsche Bank

Asked why GM-63 volumes are flat in 2026 despite a large quarterly award, and whether B-21 acceleration would be additive to 2026 EBIT or wash.

GM-63 flat due to ongoing capacity expansion investments; growth expected to reaccelerate in 2027. B-21 acceleration requires $2-3B investment over multi-year period with returns ramping over multiple years. Minimal 2026 EBIT impact; greater impact in 2027-2029.

GM-63 flat volumes in 2026 due to capacity expansionGM-63 expected to grow in 2027 and be long-term growth driver$2-3 billion investment for B-21 acceleration over multi-year periodAccelerated B-21 revenue ramping over multi-year period

Robert Stallard · Vertical Research

Asked about dividend and buyback plans, particularly given recent U.S. government commentary. Also asked about supply chain as pacing item and whether Northrop will invest own capital there.

Suspended additional buybacks beyond January 2025. Dividend increase will be decided by board in May timeframe with update at Q2 earnings. Company partnering with supply chain on capacity expansion; most suppliers investing alongside Northrop. Government addressing gaps in lower-tier supply chain (raw materials, rare earths).

No additional buybacks planned beyond January 2025Dividend increase decision deferred to May board meetingDividend increase update expected at Q2 2025 earningsNorthrop investing in CapEx for capacity; supply chain partners co-investing

Ken Herbert · RBC

Asked about international growth implications in 2026 guidance and timing of contract announcements for IBCS/IDCS, which has 20 countries expressing interest.

2026 expected to be strong year for international awards setting up 2027 growth. IDCS: U.S. and Poland expanding deployments; 2-3 additional major countries expected to announce awards in 2026. Munitions seeing double-digit international growth. Additional awards expected on airborne radar with 2027 sales impact. International content ramping on E2D and Triton.

20 countries expressed interest in IDCSU.S. and Poland continuing IDCS deployments in 20262-3 additional major countries expected to announce IDCS awards in 2026International munitions growth expected to be double-digit

Douglas Arnett · Bernstein

Asked about Sentinel program revenue trajectory given latest IFC push to end of 2033, and aeronautics segment margin guidance of mid-single-digits versus market expectations of higher margins and path to 10%.

Sentinel timeline being restructured; Air Force to firm schedule with new Milestone B and IOC/FOC ranges. Goal is to accelerate timelines from Nunn-McCurdy breach schedule. Development expected to continue several years with production transition later in decade. Aeronautics margins at mid-single-digits in 2026 driven by B-21 development work and PACMO; mature F-35 and E2D relatively stable. Long-term path to 10% margins as B-21 transitions to production and development programs mature.

Sentinel IFC pushed to end of 2033Air Force restructuring Sentinel with accelerated timeline goal versus Nunn-McCurdy scheduleSentinel development expected to continue several years; production transition later in decade2026 aeronautics margins mid-single-digits (low to mid 9%)

Answers to last quarter's watch list

Q4 revenue magnitude. Q4 revenue of $11.71B comfortably cleared the $10.85B floor implied by the FY guide low end, and FY actual of $41.95B beat the high end by $54M. The Q3 guide cut over-corrected.
Resolved positively
B-21 deal clarity timeline. For the third consecutive quarter, management said the deal is imminent — this time naming Q1 2026 as the target — but the deal still has not closed and the FY26 guide explicitly excludes accelerated production. Funding is now confirmed via the reconciliation bill, which is incremental, but the credibility of the "coming months" language is exhausted.
Continue monitoring
Space Systems return to growth. Space printed +5% in Q4, completing the inflection from -12% in Q2 → -6% in Q3 → +5%. Program wind-down lap is done.
Resolved positively
Segment OM rate sustainability. Q4 segment OM of 11.2% held flat YoY, but FY25 full-year segment OM came in at 10.4% (down 70bps), weighed down by the Q1 B-21 loss provision. FY26 guidance of $4,850–5,000M against $43.5–44.0B revenue implies an OM rate of ~11.0–11.5% — above the FY25 full-year rate but roughly flat to the Q4 exit, not expanding. The 2026 guide is roughly in line with the Q4 exit rate, not conservative as Q3 dynamics implied.
Resolved negatively
FAXX or B-21 rate inclusion in 2026 guide. Neither was folded in. Management's "balanced" framing means the upside catalysts remain deferred to 2027.
Resolved negatively
EMD/LREP cost reset magnitude. No discrete B-21 EAC charge was disclosed in the Q4 print. The cost issue flagged in Q3 appears contained, but management did not quantify or close the loop explicitly.
Continue monitoring

What to watch into next quarter

B-21 acceleration deal close by Q1 print. Management committed to this quarter. If Q1 reports and the deal is still pending — fourth consecutive quarter of "coming months" — the upside thesis has to be re-priced as a 2027 event with execution risk, not a 2026 catalyst with timing risk.

FY26 revenue guide trajectory. Q1 sales guided "low single digits" with growth expected to accelerate through the year, mirroring the 2025 cadence. Watch whether Q1 prints at the low end (suggesting cushion) or the high end (suggesting the full-year acceleration is at risk). 2H weighting puts roughly $22B+ of revenue in H2 against the $43.75B midpoint.

Segment OM rate vs. FY26 implied ~11.2%. The guide bakes in flat-to-slightly-down OM rate vs. the Q4 exit. Watch Q1 segment OM — if it tracks above 11.5%, the FY26 guide is again conservative; if it prints below 11%, the "margin expansion over time" thesis gets pushed further out.

IDCS award conversion. Management expects 2–3 additional country announcements in 2026. The first announcement timing — and whether award sizes are material vs. the Poland baseline — determines how much international can carry the 2027 growth bridge.

Capital return decisions at Q2 print. Buybacks suspended beyond January 2026, dividend deferred to May. The shape of the May board decision will signal whether management views the CapEx-heavy 2026–2027 phase as fully self-funded or requires sustained free cash flow retention.

GEM 63 inflection in 2027. Flat in 2026 due to capacity build. Watch for early commentary on 2027 volume ramp tied to Amazon Project Leo and tactical missile system qualifications — this is the cleanest signal on whether the speculative capacity CapEx is converting to backlog.

Sources

  1. NOC Q4 2025 earnings release (SEC filing): https://www.sec.gov/Archives/edgar/data/1133421/000113342126000002/noc-12312025xearningsrelea.htm
  2. NOC Q4 2025 earnings call commentary (as captured in tone and Q&A extraction)

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.